Kura Oncology to Present First FLT3 Combination Data at ASH

Eight ziftomenib abstracts were accepted for presentation at the 2026 ASH Annual Meeting, including preliminary clinical findings from combinations with quizartinib and gilteritinib and longer-term frontline data.